By Gina Kolata The blockbuster drug semaglutide, sold as Ozempic for diabetes and as Wegovy for weight loss, now has a new ...

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

Osteoarthritis, the most common form of arthritis, is primarily caused by wear and tear on the protective layer of cartilage ...

All doses of Novo Nordisk’s blockbuster diabetes and obesity drugs were listed as available on the FDA shortage list as of ...

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

New research shows that weight loss drugs semaglutide, known as Ozempic and Wegovy, not only aid in weight loss but also ...

Subcutaneous semaglutide is currently marketed under the brand name Wegovy for chronic weight management and to reduce the risk of major adverse cardiovascular events in adults with established ...

"Obesity-related knee osteoarthritis is a progressive condition that can lead to pain and stiffness of the knee and impair ...

Discover the potential of semaglutide, the active ingredient in Ozempic and Wegovy, for reducing body weight and knee osteoarthritis-related pain.

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weig ...